| Literature DB >> 35326981 |
Haya M Almalag1, Wael H Mansy1, Abdulrahman M Alwhaibi1, Wajid Syed1, Salmeen D Babelghaith1, Mohamed N Al Arifi1.
Abstract
BACKGROUND: The role of community pharmacists (CPs) in various healthcare settings is well documented in the literature including providing safe and easy access to medications. Oral contraceptives (OCPs) are the most frequently used method of terminating unwanted pregnancies worldwide.Entities:
Keywords: Saudi Arabia; community pharmacists; knowledge; oral contraceptives; willingness
Year: 2022 PMID: 35326981 PMCID: PMC8956115 DOI: 10.3390/healthcare10030503
Source DB: PubMed Journal: Healthcare (Basel) ISSN: 2227-9032
Figure 1Number of oral contraceptives prescribed or sold weekly.
Demographic data of the community pharmacists (n = 347).
| Variables | |
|---|---|
| Age (years) | |
| 25–35 | 267 (76.9) |
| 36–45 | 68 (19.6) |
| 46–55 | 11 (3.2) |
| 56–65 | 1 (0.3) |
| Work setting | |
| Chain CPs | 297 (85.6) |
| Independent CPs | 50 (14.4) |
| Years of experience | |
| <6 months | 59 (17.0) |
| 6–24 months | 99 (28.5) |
| >24 months | 189 (45.5) |
| Years of practice as a community pharmacist | |
| <1 | 80 (23.1) |
| from 1 to <5 | 90 (25.9) |
| from 5 to <10 | 103 (29.7) |
| from 10 to <20 | 65 (18.7) |
| >20 | 9 (2.6) |
| Country of graduation | |
| Saudi Arabia | 193 (55.6) |
| Egypt | 109 (31.4) |
| Other | 39 (11.2) |
| Number of oral contraceptives prescribed or sold weekly | |
| 1–3 prescriptions | 121 (34.9) |
| 4–6 prescriptions | 81 (23.3) |
| >6 prescriptions | 145 (41.8) |
| Education about oral contraceptives * | |
| Yes | 306 (88.2) |
| No | 32 (9.2) |
* Missing data.
The general knowledge of the CPs regarding oral contraceptives.
| Variables | |
|---|---|
| Indications of tableted oral contraceptives | |
| Pregnancy prevention | 309 (89.0) |
| Acne | 109 (31.4) |
| Hirsutism | 73 (21.0) |
| Menstrual cramps | 79 (22.8) |
| Anemia due to iron deficiency | 24 (6.9) |
| Side effects | |
| Irregular bleeding | 197 (56.8) |
| Nausea | 172 (49.6) |
| Weight gain | 266 (76.7) |
| Mood swings | 257 (74.1) |
| Tenderness of the breast | 146 (42.1) |
| Headache | 169 (48.7) |
| Contraindications | |
| Migraine | 98 (28.2) |
| Liver tumor | 32.6 (113) |
| Breast cancer | 237 (68.3) |
| Deep vein thrombosis | 227 (65.4) |
| Drug–drug interactions | |
| Antibiotic | 177 (51.0) |
| Antiepileptic | 213 (61.4) |
| I do not know | 26 (7.5) |
| Indications of progestin-only tablets | |
| Breastfeeding | 250 (72.0) |
| Active liver | 54 (15.6) |
| Breast cancer within 5 years | 102 (29.4) |
Pharmacists’ knowledge about proper use and missed doses.
| Question | |
|---|---|
| Starting day | |
| Day 1–5 of the cycle, continued for 21 days, followed by a 7-day tablet-free interval | 243 (70.0) |
| Day 1–7 of the cycle, continued for 21 days, followed by a 7-day tablet-free interval | 79 (22.8) |
| Day 1–10 of the cycle, continued for 21 days, followed by a 7-day tablet-free interval | 6 (1.7) |
| I do not know | 19 (5.5) |
| Missed dose in the first week | |
| Take a new tablet and use additional precautions for the next week | 228 (65.7) |
| Do not take a new tablet, only use additional precautions throughout the next week | 94 (27.1) |
| I do not know | 25 (7.2) |
| Missed dose in the second and third weeks | |
| Take a new tablet and use additional precautions and omit the tablet-free interval | 101 (29.1) |
| Take a new tablet and use additional precautions throughout the next week | 126 (36.3) |
| Do not take a new tablet, only use additional precautions throughout the next week | 86 (24.8) |
| I do not know | 34 (9.8) |
| Take only progesterone tablets | |
| Daily at the same time | 287 (82.7) |
| Any time | 42 (12.1) |
| I do not know | 18 (5.2) |
Community pharmacists’ score of knowledge regarding proper use and missed doses.
| Variables | Median (IQR) | |
|---|---|---|
| Age groups | 0.481 | |
| 25–35 | 3 (1) | |
| 36–45 | 2 (1) | |
| 46–55 | 2 (1) | |
| Type of pharmacy | 0.013 | |
| Chain | 3 (1) | |
| Independent | 2 (2) | |
| Years working at community pharmacies in Saudi Arabia | 0.003 | |
| <6 months | 2 (2) | |
| 6–24 months | 2 (1) | |
| >24 months | 3 (1) | |
| Years of practice as a community pharmacist | 0.001 | |
| <1 | 2 (2) | |
| from 1 to <5 | 2 (1) | |
| from 5 to <10 | 3 (1) | |
| from 10 to <20 | 3 (1) | |
| >20 | 2 (1) | |
| Country of graduation | 0.052 | |
| Kingdom of Saudi Arabia | 2 (1) | |
| Egypt | 3 (1) | |
| Other | 2 (1) | |
| Education about oral contraceptives | 0.205 | |
| Yes | 3 (1) | |
| No | 2 (2) |
Reasons for the community pharmacists’ willingness to prescribe oral contraceptives.
| Reasons | Agree | Neutral | Disagree |
|---|---|---|---|
| Improved access and advice will benefit patients | 290 | 43 | 14 |
| Pharmacy staff are well-qualified and well-educated to prescribe and counsel on oral contraceptives | 256 | 65 | 25 |
| If OCP tablets are available in pharmacies, they may increase compliance * | 243 | 86 | 18 |
| Pharmacists’ professional development | 265 | 66 | 16 |
| A significant public health concern ** | 273 | 58 | 16 |
| Relationships with local physicians or clinics should be strengthened | 256 | 68 | 23 |
| Increased business/revenue | 195 | 106 | 23 |
* Significant difference with education about OCPs (p = 0.003). ** Significant difference with years working at a community pharmacy in Saudi Arabia (0.001).
Barriers that prevent CPs from prescribing oral contraceptive.
| Reasons | Agree | Neutral | Disagree |
|---|---|---|---|
| Pharmacists are busy to prescribe oral contraceptives * | 103 | 89 | 155 |
| Increased workload | 159 | 85 | 102 |
| Patient safety is a major concern | 268 | 51 | 28 |
| Insufficient training | 153 | 96 | 98 |
| Reduced trust in pharmacist competency to prescribe oral contraceptives | 135 | 81 | 131 |
| Physician’s resistance | 189 | 111 | 47 |
| Objections based on religion ** | 128 | 112 | 47 |
* Significant difference with the practice site (0.038) ** Years working at a community pharmacy in Saudi Arabia (p = 0.009).